FDA Accepts Bridge Biotherapeutics' Investigational New Drug Application for Lung Cancer Drug

NEW YORK – Seongham, South Korea-based biotech company Bridge Biotherapeutics said the US Food and Drug Administration has accepted its investigational new drug application for BBT-176, allowing the firm to start studying the drug in non-small cell lung cancer patients who have become resistant to osimertinib (AstraZeneca's Tegrisso) due to EGFR C787S mutations.